Loading…
Lobbying Spend
—
Filings
3
Firms Hired
1
Active Period
2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · third_quarter · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Most Favored Patient Act of 2026
2026 · third_quarter · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7837
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7871
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · second_quarter · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Most Favored Patient Act of 2026
2026 · second_quarter · Firm: GRIDIRON PUBLIC AFFAIRS, LLC
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7837
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7871
Source: Senate LDA